低分子量肝素钙注射液致弥漫性肺泡出血一例_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 高志英 ¹ , 王浩 ² , 李玉秀 ¹ , 周宏刚 ¹ , 马文 ² , 罗玉 ²

1. ;
2. ;

Corresponding author：

Keywords：

DOI：

10.7507/1671-6205.202402043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 高志英, 王浩, 李玉秀, 周宏刚, 马文, 罗玉. 低分子量肝素钙注射液致弥漫性肺泡出血一例. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(5): 355-358. doi: 10.7507/1671-6205.202402043 Copy

1.	Junqueira DR, Perini E, Penholati RR, et al. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev, 2012, 12(9): CD007557.
2.	周武, 曹发奇, 曾睿寅, 等. 创伤骨科患者围术期下肢静脉血栓形成诊断及防治专家共识(2022年). 中华创伤杂志, 2022, 38(1): 23-31.
3.	Mendes D, Penedones A, Martins M, et al. Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: a case series of five patients. Clin Case Rep, 2020, 8(12): 3432-3439.
4.	Yang X, Li N, Guo T, et al. Comparison of the effects of low-molecular-weight heparin and fondaparinux on liver function in patients with pulmonary embolism. J Clin Pharmacol, 2020, 60(12): 1671-1678.
5.	孙丽, 高雷, 李霖, 等. 低分子肝素诱发肝损伤: 个案报道并文献统计分析. 中国现代应用药学, 2023, 40(2): 243-248.
6.	Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest, 2010, 137(5): 1164-1171.
7.	鲍隽君, 韩一平, 萧毅, 等. 弥漫性肺泡出血. 中国呼吸与危重监护杂志, 2010, 9(6): 649-651.
8.	方芳, 李燕明, 胡松涛, 等. 弥漫性肺泡出血的临床和病理学特征. 中华医学杂志, 2016, 96(2): 108-112.
9.	Bhushan A, Choi D, Maresh G, et al. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int, 2022, 42(3): 485-492.
10.	Alexandre AT, Vale A, Gomes T. Diffuse alveolar hemorrhage: how relevant is etiology? Sarcoidosis Vasc Diffuse Lung Dis, 2019, 36(1): 47-52.
11.	Vasić. NR, Milenković BA, Pešut DP, et al. Drug induced lung disease-amiodarone in focus. Med Pregl, 2014, 67(9-10): 334-337.
12.	Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med, 2004, 25(1): 133-140.
13.	Scharbert G, Gebhardt K, Sow Z, et al. Point-of-care platelet function tests: detection of platelet inhibition induced by nonopioid analgesic drugs. Blood Coagul Fibrinolysis, 2007, 18(8): 775-780.
14.	药品不良反应报告和监测管理办法培训教材. 北京: 中国医药科技出版社, 2012.
15.	Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981, 30(2): 239-245.
16.	Hayashi S, Maruoka S, Nakagawa Y, et al. Diffuse alveolar hemorrhage associated with low molecular weight heparin. Respirol Case Rep, 2013, 1(1): 2-4.
17.	Yıldırım F, Kara İ, Okuyan H, et al. Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention. Clin Respir J, 2017, 11(6): 1071-1073.
18.	Park JA. Treatment of diffuse alveolar hemorrhage: controlling inflammation and obtaining rapid and effective hemostasis. Int J Mol Sci, 2021, 22(2): 793.
19.	郝兴亮, 纪艳荣, 张建, 等. 药物性弥漫性肺泡出血一例. 中国呼吸与危重监护杂志, 2022, 21(12): 890-892.

1. Junqueira DR, Perini E, Penholati RR, et al. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev, 2012, 12(9): CD007557.
2. 周武, 曹发奇, 曾睿寅, 等. 创伤骨科患者围术期下肢静脉血栓形成诊断及防治专家共识(2022年). 中华创伤杂志, 2022, 38(1): 23-31.
3. Mendes D, Penedones A, Martins M, et al. Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: a case series of five patients. Clin Case Rep, 2020, 8(12): 3432-3439.
4. Yang X, Li N, Guo T, et al. Comparison of the effects of low-molecular-weight heparin and fondaparinux on liver function in patients with pulmonary embolism. J Clin Pharmacol, 2020, 60(12): 1671-1678.
5. 孙丽, 高雷, 李霖, 等. 低分子肝素诱发肝损伤: 个案报道并文献统计分析. 中国现代应用药学, 2023, 40(2): 243-248.
6. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest, 2010, 137(5): 1164-1171.
7. 鲍隽君, 韩一平, 萧毅, 等. 弥漫性肺泡出血. 中国呼吸与危重监护杂志, 2010, 9(6): 649-651.
8. 方芳, 李燕明, 胡松涛, 等. 弥漫性肺泡出血的临床和病理学特征. 中华医学杂志, 2016, 96(2): 108-112.
9. Bhushan A, Choi D, Maresh G, et al. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int, 2022, 42(3): 485-492.
10. Alexandre AT, Vale A, Gomes T. Diffuse alveolar hemorrhage: how relevant is etiology? Sarcoidosis Vasc Diffuse Lung Dis, 2019, 36(1): 47-52.
11. Vasić. NR, Milenković BA, Pešut DP, et al. Drug induced lung disease-amiodarone in focus. Med Pregl, 2014, 67(9-10): 334-337.
12. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med, 2004, 25(1): 133-140.
13. Scharbert G, Gebhardt K, Sow Z, et al. Point-of-care platelet function tests: detection of platelet inhibition induced by nonopioid analgesic drugs. Blood Coagul Fibrinolysis, 2007, 18(8): 775-780.
14. 药品不良反应报告和监测管理办法培训教材. 北京: 中国医药科技出版社, 2012.
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981, 30(2): 239-245.
16. Hayashi S, Maruoka S, Nakagawa Y, et al. Diffuse alveolar hemorrhage associated with low molecular weight heparin. Respirol Case Rep, 2013, 1(1): 2-4.
17. Yıldırım F, Kara İ, Okuyan H, et al. Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention. Clin Respir J, 2017, 11(6): 1071-1073.
18. Park JA. Treatment of diffuse alveolar hemorrhage: controlling inflammation and obtaining rapid and effective hemostasis. Int J Mol Sci, 2021, 22(2): 793.
19. 郝兴亮, 纪艳荣, 张建, 等. 药物性弥漫性肺泡出血一例. 中国呼吸与危重监护杂志, 2022, 21(12): 890-892.

Previous Article
隐源性机化性肺炎的临床特点分析
Next Article
血液净化在新型冠状病毒感染中的应用

Chinese Journal of Respiratory and Critical Care Medicine

低分子量肝素钙注射液致弥漫性肺泡出血一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content